Member Info for SGD27

The presentation has just appeared :

https://www.synairgen.com/wp-content/uploads/2020/07/200720-Synairgen-data-readout-final-version.pdf

@cg_race : Here's another way you could look at it.

Imagine all your shares were sold (at today's prices, NOT what you paid for them). So now you have £X000 in the bank and no shares.

Starting from scratch, but based on the research you've done, decide what shares you think you should invest in, and in what proportions.

Compare that with what you actually have now, and make the necessary adjustments (ignoring small changes, because of the transaction costs).

Many investment books suggest this kind of approach, that history should be ignored because it can't be changed, and will also acknowledge that it's psychologically very difficult to do! It's one of the reasons that humans aren't always very good at investing.

"Everything you need to know about the COVID-19 therapy trials"

SNG001 is duly included in the list.

https://www.pharmaceutical-journal.com/news-and-analysis/features/everything-you-need-to-know-about-the-covid-19-therapy-trials/20208126.article

That's how I see it too. SNG001 is aimed at a particular COPD niche - a short-term treatment for viral exacerbations. Verona refer to ensifentrine as a "maintenance treatment", so quite different as far as I can see (as a non-expert).

@gollumk :

https://youtu.be/npEFq4AiuIY

I believe hospital & home are technically parts of the same trial (SG016). Hence hospital-only results would be classed as interim.

@ChrisToffer : Thanks for getting clarification on dosing.

Now you're in their good books ,I suppose you couldn't just see if they had any comments on the Amiens trial?! :-)

@ChrisToffer : Yes, and that makes it a bit hard to understand what exactly is motivating them to start this new trial now. (If it was in some sort of collaboration with SNG we'd surely have been informed in an RNS by now.)

I'm just wondering about the patent situation. This one seems to cover 1a & 1b :

https://patents.justia.com/patent/9421243

This French trial looks new. Inhaled IFN Beta 1b - couldn't be much closer!

It's open label though, and they haven't even started recruiting yet.

https://www.clinicaltrials.gov/ct2/show/NCT04469491

Don't think this has been posted yet, apols if it has. It's specifically about Synairgen.

https://www.trialsitenews.com/can-inhaled-interferon-beta-prevent-worsening-or-accelerate-recovery-of-severe-respiratory-track-infections-associated-with-covid-19/

There were quite a few people talking about derisking by selling in the approach to results

... and same people saying they expect the SP to rise in the approach to results.

That doesn't quite square up does it!

@CapitalCity (Sat 21:05) : Many thanks for posting the video. I've been following Dr Fish's work, but hadn't come across that detailed presentation before.

Interesting point near the end (~51:50): they had a clear positive effect even though she thought their delivery device was "not a great system". Ours probably is/are much more efficient.

Anyone thinking of investing in Pasofino will have to wait as trading is temporarily suspended, not surprisingly.

BTW they have a discussion board here :

https://ceo.ca/VEIN

(It's still under their previous name - Enforcer Gold.)

Re yesterday's RNS :

https://www.vo%78markets.co.uk/articles/arix-bioscience-russ-mould-on-the-fed-paul-hill-on-boohoo-edac6b4

Anticipating FDA approval of Atox Bio's Reltecimod around April/May 2021.

https://uk.reuters.com/article/uk-health-coronavirus-eu-merck/merck-says-it-has-agreed-to-supply-potential-covid-19-drug-rebif-to-eu-countries-idUKKBN2492H4

https://www.sciencemag.org/news/2020/07/can-boosting-interferons-bodys-frontline-virus-fighters-beat-covid-19

Our trial mentioned (though not by name).

"People who suffer mild Covid-19 symptoms may carry protective antibodies for only a matter of weeks, potentially complicating the search for a vaccine, a study suggests."

https://www.thetimes.co.uk/article/coronavirus-antibody-protection-may-only-last-weeks-v3nflbgcb

(needs subscription for full access).

Looks like a nonevent to me - shares moved from JAM to JFM :

"As of 1 July 2020, following Jupiter's acquisition of Merian, the Chain of Control for Jupiter Fund Management plc, which includes Jupiter Asset Management, has changed and any disclosures going forward will be notified by Jupiter Fund Management Plc (JFM). As such this disclosure indicates that JAM no longer has responsibility for filing TR1 notifications and this responsibility has been transferred to JFM as the parent entity."

Hi T6.1, the powers that be don't let new posters do links for a while. Try adding a few spaces so that it no longer looks like a link - then someone else can re-post it.